Teva launches QVAR RediHaler inhalation aerosol in US

QVAR^® RediHaler^™ is the first and only breath-actuated aerosol inhaled corticosteroid for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and older. It is not indicated for the relief of acute bronchospasm.

QVAR^® RediHaler^™ differs from conventional metered-dose inhalers (MDIs) as it delivers medication via a breath-actuated inhaler, eliminating the need for hand-breath coordination during inhalation.

QVAR^® RediHaler^™ administers the same active ingredient found in the previously available QVAR^® (beclomethasone dipropionate HFA) Inhalation Aerosol, but utilizes innovative breath-actuated inhaler technology. QVAR^® RediHaler^™ was also designed to be ready for use, with no shaking or priming needed. Because the medication delivery is breath actuated, it should not be used with a spacer or volume holding chamber.

Teva North America commercial executive vice president Brendan O’Grady said: “QVAR^® has been an available asthma treatment option for well over a decade, so we are excited by the new technology of QVAR^® RediHaler^™ that directly addresses an unmet need in the field of asthma management.”

With the launch of QVAR^® RediHaler™, Teva is discontinuing sales of the previously available QVAR^®. Patients currently prescribed QVAR^® and/or their caregivers are encouraged to speak with a healthcare professional about how this new treatment option may impact their treatment plan and how to obtain and use QVAR^® RediHaler^™, if desired. QVAR^® RediHaler^™ will be priced at parity to QVAR^®.

QVAR^® RediHaler™ (beclomethasone dipropionate HFA) Inhalation Aerosol is a breath-actuated inhaled prescription medicine used as a maintenance treatment for the prevention and control of asthma in people 4 years of age and older.

QVAR^® RediHaler^™ Inhalation Aerosol is not used to relieve sudden breathing problems and won’t replace a rescue inhaler.